Prolonged Medication Shortages Threaten Quality of Life for ADHD Patients
-
Loading... - Adio Tarek
- 13 Mar 2025
- 31 Views
- 0 Like
- 0 Comment
Hundreds of individuals with Attention Deficit Hyperactivity Disorder (ADHD) in Cyprus are facing serious risks to their health and well-being due to prolonged shortages of essential pharmaceutical treatments. The situation has raised significant concern among psychiatrists, psychologists, the Ministry of Health, and the Health Insurance Organisation, prompting a high-level meeting aimed at finding solutions to this pressing crisis.
Marina Georgiou, president of the ADHD Association, highlighted the critical nature of consistent medication for those with ADHD. “When a person with ADHD cannot consistently receive their medication, they begin to develop problems which, in some cases, put them at risk,” she stated. For instance, a child who misses their medication may exhibit aggressive behavior, while an adult with diminished concentration could pose a danger on the road.
The specific medications in question—Concerta and Atomoxetine—have been in short supply for the past three years, with the current shortage persisting since late 2024. Georgiou noted that only small stocks are expected to arrive in the near future. Relevant departments within the Ministry of Health, including the Directorate of Purchases and Supplies and the Pharmaceutical Services, are actively working to secure sufficient quantities to meet the needs of all patients requiring these medications.
The shortage has been attributed to insufficient stock from manufacturers, which has also impacted exports from some EU countries. In Cyprus, approximately 700 packages of each medication are anticipated to arrive, but this quantity may not be adequate to cover the needs of ADHD patients for even a month.
During the recent meeting, officials decided to pursue authorization for alternative formulations used in other countries while intensifying efforts to import larger quantities of the two medications as soon as possible. A deadline of March 21 has been set for all stakeholders to reconvene and determine the next steps to address the growing shortfall.
Georgiou emphasized the importance of medication in managing ADHD, stating, “Medication is a fundamental pillar in managing ADHD, directly affecting individuals’ functionality, whether in education for children or in work, social life, and daily activities for adults.” The prolonged shortage of these specific medications is having a serious impact on the health and quality of life of people with ADHD, with potential negative consequences for their interpersonal relationships.
As the situation develops, it remains crucial for authorities to act swiftly to ensure that individuals with ADHD receive the necessary treatments to maintain their health and well-being.
